Related Experiment Video
Updated: Apr 7, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies
Meenakshi Malhotra1, André Toulouse, Bruno M D C Godinho
1Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland.
Abstract:
Malignant primary brain tumors are aggressive cancerous cells that invade the surrounding tissues of the central nervous system. The current treatment options for malignant brain tumors are limited due to the inability to cross the blood-brain barrier. The advancements in current research has identified and characterized certain molecular markers that are essential for tumor survival, progression, metastasis and angiogenesis. These molecular markers have served as therapeutic targets for the RNAi based therapies, which enable site-specific silencing of the gene responsible for tumor proliferation. However, to bring about therapeutic success, an efficient delivery carrier that can cross the blood-brain barrier and reach the targeted site is essential. The current review focuses on the potential of targeted, non-viral and viral particles containing RNAi therapeutic molecules as delivery strategies specifically for brain tumors.
Insights
Targeted RNAi therapies show promise for brain tumors by silencing specific genes. Efficient delivery across the blood-brain barrier is key for these novel treatments to succeed.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Biotechnology
Background:
- Malignant brain tumors are aggressive and difficult to treat due to the blood-brain barrier.
- Current therapies are limited in their ability to reach and effectively treat brain tumors.
Purpose of the Study:
- To review the potential of RNA interference (RNAi) therapies for brain tumors.
- To explore delivery strategies for RNAi therapeutics across the blood-brain barrier.
Main Methods:
- Focus on molecular markers essential for tumor survival and progression.
- Investigate RNAi-based therapies targeting these molecular markers.
- Review targeted, non-viral, and viral delivery systems for RNAi molecules.
Main Results:
- Molecular markers identified as therapeutic targets for RNAi.
- RNAi enables site-specific gene silencing to inhibit tumor proliferation.
- Development of efficient delivery carriers is crucial for therapeutic success.
Conclusions:
- Targeted delivery systems are essential for effective RNAi therapy in brain tumors.
- Non-viral and viral particles show potential for crossing the blood-brain barrier.
- RNAi holds promise for treating malignant brain tumors.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...